RDHL reported disappointing Ph3 Crohns Dissease trial results 7/31/18. This trial took the novel approach of treating CD as an infection rather than a complex inflammation.
The CD treatment space is increasingly competitive. Although safe, RDHL's approach should include a diagnostic to prove the concept. In any case, it should run another Ph3 trial.
RDHL's H Pylori treatment has a higher probability of success. Trial results for this program will be available Q4/18
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.